Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. There is evidence that oxidative stress is implicated in the pathophysiology of the neurodegenerative disorders, including ALS. Data from the literature suggests that the receptor for advanced glycation end products (RAGE) participates in pathological conditions, including oxidative stress and neurodegeneration. MATERIALS AND METHODS: The study involved 20 patients with ALS and 20 patients from the control group. The serum-soluble RAGE (sRAGE) levels were measured using the enzyme-linked immunosorbent method. RESULTS: The study showed that sRAGE levels are significantly decreased in serum of the patients with ALS comparing to the control group (P < 0.05). The correlation between the serum sRAGE levels and clinical parameters of the disease was not significant (P > 0.05). CONCLUSIONS: The results indicate that sRAGE participates in pathophysiology of the ALS. It is possible that low sRAGE levels may influence neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
Lue, L.-F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., Stern, D. M., & Yan, S. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7732 · Cited by 439
Bucciarelli, L. G., Wendt, T., Rong, L., Lalla, E., Hofmann, M. A., Goova, M. T., Taguchi, A., Yan, S. F., Yan, S. D., Stern, D. M., et al. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8491-x · Cited by 304
Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.007 · Cited by 148
Cited by
Sparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 622
Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View
Cenini, G., Lloret, A., & Cascella, R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2105607 · Cited by 499
High-Mobility Group Box 1, Oxidative Stress, and Disease
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3356 · Cited by 468
Derk, J., MacLean, M., Juranek, J., & Schmidt, A. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000421 · Cited by 96
MacLean, M., Derk, J., Ruiz, H. H., Juranek, J. K., Ramasamy, R., & Schmidt, A. M. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.012 · Cited by 69
Metadata
- Authors
- Iłżecka, J.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Hindawi Limited
- Published
- 2009-08
- Volume
- 120
- Issue
- 2
- Pages
- 119-122
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W1969932412
- Cited by
- 46
- References
- 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1111/j.1600-0404.2008.01133.x
- The paper
- Iłżecka, J. (2009). Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.2008.01133.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.